Recombinant human plasma gelsolin
Also known as: BioAegis rhu-pGSN, GELSOL, pGSN, Plasma gelsolin replacement therapy, recombinant plasma gelsolin, rhu-pGSN
Source Recombinant human plasma gelsolin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant human plasma gelsolin (rhu-pGSN) is a biologic designed to restore depleted plasma gelsolin levels in acute inflammatory states such as sepsis and ARDS.
Mechanism of Action
binds extracellular actin and modulates inflammatory signaling, reducing cytokine release and tissue injury
Routes of Administration
Goals & Uses
- Sepsis treatmentInfectious DiseaseModerate
- Acute respiratory distress syndromePulmonaryModerate
- Scavenging extracellular actin in critical illnessPathophysiology CorrectionModerate
- Acute kidney injury prevention in critical illnessNephrologyLow
- Attenuation of ARDS / acute lung injuryCritical Care / PulmonologyModerate
- Reduction of systemic inflammation in sepsisAnti Inflammatory / Critical CareLow
- COVID-19 severe disease managementInfectious Disease / Critical CareLow
Contraindications
- Known hypersensitivity to gelsolin productAllergyHigh
- Severe uncontrolled coagulopathyHematologyModerate
- Known hypersensitivity to recombinant human proteins or CHO-derived productsAllergy / ImmunologyHigh
Adverse Effects
- Headache / myalgiaGeneralUncommon
- Anti-drug antibody formationImmunologicalUnknown
- Infusion-related reactionsHypersensitivityUncommon
- Transient hypotensionCardiovascularRare
Drug Interactions
- Other recombinant protein biologicsLow
- Anticoagulants (e.g., heparin, warfarin)Low
- Concomitant immunosuppressantsModerate
Population Constraints
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveRelative
- Patients with pre-existing autoimmune conditionsImmunologicRelative
- Pregnant womenReproductiveRelative
- Renal or hepatic impairmentOrgan DysfunctionRelative
Regulatory Status
- European UnionInvestigationalUnder EMA scientific advice
- United StatesInvestigationalPhase II/III clinical trials for sepsis
- United KingdomInvestigationalNo MHRA approval. Clinical trial access only.
No FDA, EMA, or MHRA marketing approval as of 2024. Designated as an orphan drug candidate for certain indications in exploratory trials. Developed primarily by BioAegis Therapeutics. Multiple Phase I/II trials conducted.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Recombinant human plasma gelsolin?
Recombinant human plasma gelsolin (rhu-pGSN) is a biologic designed to restore depleted plasma gelsolin levels in acute inflammatory states such as sepsis and ARDS.
What is Recombinant human plasma gelsolin used for?
Recombinant human plasma gelsolin is educationally associated with: Sepsis treatment, Acute respiratory distress syndrome, Scavenging extracellular actin in critical illness, Acute kidney injury prevention in critical illness, Attenuation of ARDS / acute lung injury, Reduction of systemic inflammation in sepsis, COVID-19 severe disease management. Educational only — not medical advice.
How is Recombinant human plasma gelsolin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Recombinant human plasma gelsolin?
Reported adverse effects include: Headache / myalgia, Anti-drug antibody formation, Infusion-related reactions, Transient hypotension. This list is not exhaustive — consult a qualified clinician.
Who should avoid Recombinant human plasma gelsolin?
Recorded contraindications: Known hypersensitivity to gelsolin product, Severe uncontrolled coagulopathy, Known hypersensitivity to recombinant human proteins or CHO-derived products. Consult a qualified clinician before use.